Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1419&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1420&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1418&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "15887", "attributes": { "award_id": "1R44AI186871-01A1", "title": "AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32536, "first_name": "DIPANWITA", "last_name": "BASU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-10", "end_date": "2028-08-31", "award_amount": 1004473, "principal_investigator": { "id": 44323, "first_name": "Timothy", "last_name": "Notton", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44324, "first_name": "Ariel", "last_name": "Weinberger", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3392, "ror": "", "name": "AUTONOMOUS THERAPEUTICS, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This Phase II SBIR will de-risk a new class of antivirals that can be developed to target any RNA virus from SARS-CoV-2 to influenza. The effort will specifically translate a lead, platform-derived SARS-CoV-2 candidate (AT191) designed to be self-administered and to prevent hospitalizations or deaths by any SARS-CoV-2 variant. Despite vaccines and 2 blockbuster antivirals marketed to prevent hospitalizations, 900,000 Americans were hospitalized due to SARS-CoV-2 in 2023. Beyond vaccine hesitancy and durability concerns, existing antivirals only reduce hospitalizations and deaths by 40–50%. SARS-CoV-2 antivirals are further limited by contraindications (e.g. Paxlovid) and safety concerns (e.g. molnupiravir). Moreover, there is a risk that SARS- CoV-2 acquires resistance to all existing classes of antivirals—as occurred with all SARS-COV-2 monoclonal antibodies prior to 2024. There is a clear unmet need for new classes of antivirals, especially antivirals that can: (i) be used at-home to prevent hospitalizations, and (ii) maintain (variant-proof) efficacy as novel variants emerge. Encrypted RNA (encRNA) is a new class of RNA developed by Autonomous Therapeutics. The plug-and-play platform technology can develop antivirals against any RNA virus and can encode any therapeutic protein. Unlike state-of-the-art mRNA, each platform-derived encRNA only activates its (broad-spectrum) antiviral payload in targeted virus-infected cells. More specifically, encRNA only translate encoded proteins when bound, transcribed, and amplified by targeted viral RNA polymerase (RdRp) complexes conserved across a viral species. Thus, encRNA remain translationally inactive and safe in uninfected cells (e.g. as prophylactics). AT191 is our lead, first-in-class encRNA therapeutic candidate developed to confer inhaled and variant-proof efficacy against all variants of SARS-CoV-2 (and SARS-CoV-1). AT191 confers precision and pan-sarbecovirus efficacy—because AT191’s antiviral payload (IFN-β) is only activated and translated by sarbecovirus RdRp. In Phase I-equivalent studies, we developed: (i) the encRNA platform technology, (ii) the AT191 lead candidate, and (iii) an inhalable lipid nanoparticle (LNP) for encRNA self-administration using marketed nebulizers. We further demonstrated the (iv) variant-proof efficacy of AT191 against every tested SARS-CoV-2 variant in vitro, and the (v) preliminary in vivo safety and efficacy of AT191 in both mice and hamsters. Here we propose to develop AT191 into a GLP-ready candidate ready for IND-enabling studies. We propose to test the pan-sarbecovirus efficacy (SARS-CoV-1 & 2) of AT191 in vivo and to perform critical CMC, inhalation, dose-timing, and dose-finding studies in hamsters. We will also test safety/efficacy in non-human primates. The effort will culminate in a pre-IND. If successful in follow-on clinical studies, AT191 could be used at-home as a prophylactic or therapeutic: e.g. for immediate use after exposure to an infected child or family member. Beyond SARS-CoV-2, the same encRNA-LNP platform technology could be used to develop precision and variant-proof candidates for any RNA virus—including viruses for which no safe and effective antivirals exist.", "keywords": [ "2019-nCoV", "Ablation", "American", "Anti-viral Agents", "Binding", "Biological Assay", "Biological Products", "COVID-19", "COVID-19 testing", "COVID-19 therapeutics", "Cell Culture Techniques", "Cells", "Cessation of life", "Child", "Chronic", "Clinical", "Clinical Research", "Colorado", "Complex", "Coronavirus", "DNA-Directed RNA Polymerase", "Data", "Death Rate", "Doctor of Philosophy", "Dose", "Evaluation", "Exposure to", "Family", "Family member", "Future", "Genetic Transcription", "Goals", "Government", "Hamsters", "Home", "Hospitalization", "In Vitro", "Individual", "Infection", "Influenza", "Influenza A virus", "Influenza B Virus", "Inhalation", "Inhalation Toxicology", "Interferon-β", "Interferons", "Lead", "Legal patent", "Macaca mulatta", "Marketing", "Mediating", "Messenger RNA", "Molecular", "Monoclonal Antibodies", "Mus", "Nebulizer", "Nucleosides", "Paracrine Communication", "Participant", "Paxlovid", "Peer Review", "Persons", "Phase", "Play", "Population", "Prodrugs", "Proteins", "Publications", "RNA", "RNA Viruses", "RNA-Directed RNA Polymerase", "Resistance", "Risk", "SARS coronavirus", "SARS-CoV-2 antiviral", "SARS-CoV-2 variant", "Safety", "Sarbecovirus", "Self Administration", "Small Business Innovation Research Grant", "Testing", "Therapeutic", "Tissues", "Translating", "Translations", "Transplant Recipients", "Treatment Efficacy", "United States National Institutes of Health", "Vaccines", "Variant", "Viral", "Viral Proteins", "Virus", "Virus Diseases", "commercialization", "design", "encryption", "hospitalization rates", "in vivo", "influenzavirus", "innovation", "lead candidate", "lipid nanoparticle", "manufacture", "molnupiravir", "nonhuman primate", "nonhuman primate models", "novel", "pre-clinical", "prevent", "prior authorization", "prophylactic", "safety testing", "scaffold", "seropositive", "technology platform", "therapeutic RNA", "therapeutic candidate", "therapeutic protein", "vaccine hesitancy", "viral RNA", "virology" ], "approved": true } }, { "type": "Grant", "id": "15888", "attributes": { "award_id": "1R01HL177556-01A1", "title": "Targeting NINJ1-mediated Plasma Membrane Rupture to Prevent Thrombosis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32532, "first_name": "RONALD Q", "last_name": "WARREN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-15", "end_date": "2030-06-30", "award_amount": 538808, "principal_investigator": { "id": 44325, "first_name": "Congqing", "last_name": "Wu", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3393, "ror": "", "name": "UNIVERSITY OF KENTUCKY", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal focuses on investigating the role of plasma membrane rupture (PMR) of pyroptotic macrophages in thrombosis and examine the potential therapeutic approaches targeting pyroptosis and PMR. Thrombotic complications remain a leading cause of morbidity and mortality worldwide. Current antithrombotic therapies target platelets and the coagulation cascade, common pathways for normal blood clotting upon injury (hemostasis) and the pathological formation of blood clot (thrombosis). These treatments often carry bleeding risks by disrupting hemostasis and do not address the inflammatory roots of thrombosis. Inflammation- dependent blood clotting is part of the body's response to pathogens, but excessive inflammation can result in thrombosis. Emerging research underscores inflammation's pivotal role in thrombosis across various conditions, including heart disease, deep vein thrombosis, sepsis, and COVID-19. Targeting PMR offers a strategy to simultaneously manage inflammation and thrombosis while preserving normal clotting mechanisms. Pyroptosis, a lytic form of cell death in monocytes/macrophages triggered by inflammasomes, is crucial in responding to bacterial infection and sterile inflammation, with PMR being a terminal event in this process. Our previous research has identified macrophage pyroptosis as a key contributor to thrombosis, through the release of microvesicles containing tissue factor (a key initiator of the coagulation cascade together with factor VII/VIIa). This mechanism is linked to PMR, highlighting PMR as a potential trigger of thrombosis and as a desirable inflammatory target. Because it is the final step in a chain of inflammatory processes, targeting PMR may carry low risk of immunosuppression. NINJ1, initially identified in nerve injury, emerges as the executioner of PMR that was previously thought to be passive and uncontrollable. This discovery unveils a potential new target for thrombosis intervention. Our preliminary studies showed reduced NINJ1 expression decreased thrombosis and the release of pyroptotic microvesicles. This research aims to investigate the role of myeloid NINJ1 in thrombosis, the mechanisms behind the release of pyroptotic microvesicles, and the feasibility of targeting pyroptosis and NINJ1-mediated PMR for thrombosis prevention. The expected results will enhance our understanding of NINJ1-mediated PMR in immune cell-induced thrombosis, potentially leading to targeted treatments for thrombosis-related conditions like heart disease, venous thromboembolism, cancer, and infectious disease.", "keywords": [ "Address", "Antibodies", "Bacteria", "Bacterial Infections", "Bacterial Proteins", "Belief", "Binding", "Blood", "Blood Coagulation Disorders", "Blood Coagulation Factor VII", "Blood Platelets", "Blood coagulation", "Body part", "COVID-19", "Cardiovascular Diseases", "Cell Adhesion Molecules", "Cell Death", "Cell membrane", "Cells", "Coagulation Process", "Communicable Diseases", "Dangerousness", "Data", "Deep Vein Thrombosis", "Disseminated Intravascular Coagulation", "Disulfiram", "Elements", "Escherichia coli", "Event", "Fibrin fragment D", "Heart Diseases", "Hemorrhage", "Hemostatic function", "Host Defense", "Immune", "Immune response", "Immunosuppression", "In Vitro", "Inflammasome", "Inflammation", "Inflammatory", "Injury", "Intervention", "Knockout Mice", "Link", "Lytic", "Macrophage", "Malignant Neoplasms", "Mediating", "Modeling", "Molecular", "Morbidity - disease rate", "Mus", "Myelogenous", "Myocardial Infarction", "Pathologic", "Pathway interactions", "Phosphatidylserines", "Plasma", "Prevention", "Process", "Research", "Risk", "Role", "Rupture", "Sepsis", "Stenosis", "Sterility", "Stroke", "Testing", "Therapeutic", "Thromboplastin", "Thrombosis", "biobank", "clinically relevant", "exposure pathway", "glycosylation", "improved", "inhibitor", "insight", "microvesicles", "monocyte", "mortality", "nerve injury", "nerve repair", "novel", "particle", "pathogen", "preservation", "prevent", "programs", "response", "sepsis mortality", "septic patients", "targeted treatment", "thrombotic", "thrombotic complications", "trafficking", "venous thromboembolism", "vesicular release" ], "approved": true } }, { "type": "Grant", "id": "15890", "attributes": { "award_id": "1R43HL176305-01A1", "title": "Development of a tissue-targeted non-thrombotic EPO derivative", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44326, "first_name": "NITIN", "last_name": "AGRAWAL", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-20", "end_date": "2026-08-31", "award_amount": 306658, "principal_investigator": { "id": 44327, "first_name": "Robert Rogers", "last_name": "Yocum", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3394, "ror": "", "name": "GENERAL BIOLOGICS, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "“Development of a tissue-targeted non-thrombotic EPO derivative.” Chronic obstructive pulmonary disease (COPD) affects 16 million people in the US and is the third leading cause of death in the world, with an estimated 500 million cases worldwide. In the US the primary cause is cigarette smoking, but in most of the world the cause is air pollution. In this disease, the airways (bronchioles) are constricted and the alveoli are distended and never fully contract. Current treatments use drug inhalers that open up the airways, but these treatments are only partially effective. In addition, about 2 million of the US COPD patients are also anemic, so that oxygen delivery is particularly poor. Erythropoietin (EPO) is a hormone that mediates the body’s response to massive blood loss (hemorrhage). EPO is used to treat anemia in kidney failure, cancer, etc., based on its stimulation of red blood cell production. EPO also has a useful tissue-protective activity that can reduce effects of oxygen limitation that damage the heart, brain, and other tissues. However, EPO also enhances blood clotting and increases frequency of heart attacks, strokes and deep vein thrombosis when given to anemic patients. To address COPD and other problems of oxygen delivery, General Biologics is developing an engineered protein, termed “EPO-H” (EPO for Hypoxia), that retains the red blood cell producing and tissue-protective activities of EPO, but lacks the blood clotting side effects. EPO-H will also have a long plasma half-life, to allow for infrequent dosing, patient convenience, and reduced burden on the health care system. The net effect should be that, compared to current commercial versions of EPO, our protein (“EPO-H”) will maintain production of red blood cells, show increase neuroprotection, and have significantly reduced or eliminated blood-clotting site effects. Natural EPO is not currently given to COPD patients or patients with disorders such as cystic fibrosis or extreme Covid-19 requiring hospitalization and mechanical ventilation. Our experimental aims are: (1) General Biologics will produce engineered protein for all of the experiments and will test the proteins for blood-based surrogate markers of hypoxia resistance and blood-clotting, to establish a dose at which the therapeutic effect is expected but side effects are not.; (2) University of Maryland will demonstrate that EPO-H can promote survival of mice in a low- oxygen environment; and also (3) demonstrate that EPO-H does not enhance clot size in a mouse model of deep vein thrombosis, even though natural EPO does increase the size of blood clots in mice with deep vein thrombosis.", "keywords": [ "Address", "Affect", "Air Pollution", "Alveolus", "Anemia", "Antibodies", "Atmosphere", "Binding", "Biological Assay", "Biological Products", "Blood - brain barrier anatomy", "Blood Platelets", "Blood Proteins", "Blood coagulation", "Blood flow", "Blood specimen", "Brain", "Bronchioles", "C57BL/6 Mouse", "COVID-19", "COVID-19 patient", "Cause of Death", "Cell Survival", "Cells", "Chimeric Proteins", "Chronic Obstructive Pulmonary Disease", "Coagulation Process", "Collaborations", "Contracts", "Core Facility", "Cystic Fibrosis", "Deep Vein Thrombosis", "Development", "Disease", "Dose", "Dose Limiting", "Drug Kinetics", "Drug usage", "Elements", "Environment", "Epoetin Alfa", "Erythrocytes", "Erythropoietin", "Erythropoietin Receptor", "Flow Cytometry", "Frequencies", "Glycophorin", "Goals", "Half-Life", "Health Care Systems", "Hematopoiesis", "Hematopoietic stem cells", "Hemorrhage", "Hormones", "Hospitalization", "Hypoxia", "Inferior vena cava structure", "Inhalators", "Kidney Failure", "Lead", "Malignant Neoplasms", "Maryland", "Measures", "Mechanical ventilation", "Mediating", "Medical", "Modeling", "Mus", "Mutate", "Mutation", "Myocardial Infarction", "Needles", "Oxygen", "Patients", "Persons", "Pharmaceutical Preparations", "Plasma", "Production", "Protein Engineering", "Proteins", "Reagent", "Research", "Resistance", "Reticulocyte count", "Reticulocytes", "Signal Transduction", "Site", "Stroke", "Surrogate Markers", "Testing", "Therapeutic", "Therapeutic Effect", "Thrombus", "Time", "Tissues", "Universities", "Ventilator", "analytical tool", "cigarette smoking", "constriction", "deprivation", "drug testing", "experimental study", "heart damage", "humanized antibody", "improved", "in vivo", "loss of function", "medical schools", "mouse model", "nanobodies", "neuroprotection", "novel", "preclinical development", "professor", "promote resilience", "resilience", "response", "side effect", "success", "thrombotic" ], "approved": true } }, { "type": "Grant", "id": "15894", "attributes": { "award_id": "1F31AI186351-01A1", "title": "Impacts of universal influenza mRNA vaccine on enhancing the efficacy of seasonal vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32831, "first_name": "JENNIFER L", "last_name": "GORDON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-28", "end_date": "2027-08-27", "award_amount": 44829, "principal_investigator": { "id": 44332, "first_name": "Phillip", "last_name": "Grovenstein", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3395, "ror": "", "name": "GEORGIA STATE UNIVERSITY", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Current influenza (flu) vaccines based on immunity to variable hemagglutinin (HA) provide low efficacy because of continuing HA antigenic changes and poor cross-protection. The flu ion channel M2 protein ectodomain (M2e) represents highly conserved epitopes and the HA-stem (HA2-fusion) is also an immune target for conferring protection against different viruses. My mentor’s lab reported that heterologous (human, swine, avian) tandem repeat M2e protein (5xM2e) could be a cross-protective immunogen and chimeric M2e-stem protein vaccine conferred broad cross-group protection. Nonetheless, the prior 5xM2e and M2e- stem protein vaccines require high doses and need to add neutralizing immunity. COVID-19 mRNA vaccines have been approved to widely immunize six-month-old children to the elderly, validating mRNA vaccine modality. My preliminary mouse study demonstrated that 5xM2e mRNA and M2e-stem mRNA vaccines (encapsulated into lipid nanoparticles, LNP) effectively induced M2e and stem IgG antibody responses at a low dose. Most innovatively, I found that 5xM2e mRNA-LNP supplemented conventional inactivated split flu vaccination significantly enhanced the immunogenicity and efficacy with a single dose, probably via transient induction of innate cytokine and chemokines. These preliminary data warrant further investigation of this novel vaccination strategy of combining cross-protective flu mRNA and conventional flu vaccines, overcoming a weakness of each vaccine platform. As supported by my preliminary data, I hypothesize that neutralizing HA immunity (HA mRNA or split) plus universal target immunity (M2e-Stem mRNA or protein) will offer increased immunogenicity leading to enhanced protection against homologous and heterologous viruses. In aim 1, I will determine the immunogenicity and efficacy of protection against homologous and antigenically different flu viruses after HA-based (HA mRNA or split) plus cross-protective antigen (M2e-stem mRNA or protein) vaccination. For aim 2 approaches, I will investigate the immune mechanisms of mRNA-LNP supplemented split- and protein-based vaccines inducing enhanced protection. The potential mechanisms to study will determine the contribution of antigen-specific humoral and cellular immunity to cross-protection, and the innate immune responses (innate cell phenotypes, cytokines, chemokines), likely leading to enhanced adaptive immunogenicity of vaccines. The roles of Fc receptor (FcR), natural killer (NK) cells, and ADCC (antibody-dependent cell-mediated cytotoxicity) in conferring cross-protection will be determined by using mutant mice and in vitro assays. The expected outcome of this project will advance our knowledge of how mRNA-LNP supplemented conventional vaccine elicits enhanced efficacy. If successful, this project could open a new avenue for research in enhancing vaccine efficacy for other pathogens.", "keywords": [ "Antibody Response", "Antigen Targeting", "Antigens", "Birds", "COVID-19", "Cells", "Cellular Immunity", "Child", "Chimeric Proteins", "Data", "Disease", "Dose", "Elderly", "Encapsulated", "Environment", "Epitopes", "Escherichia coli", "Family suidae", "Fc Receptor", "Flu virus", "Genetic", "Glycoproteins", "Head", "Hemagglutinin", "Human", "Humoral Immunities", "Immune", "Immune Targeting", "Immune system", "Immunity", "Immunize", "Immunoglobulin G", "Immunology procedure", "Influenza", "Influenza vaccination", "Innate Immune Response", "Investigation", "Ion Channel", "Knowledge", "Length", "M2 protein", "Mediating", "Mentors", "Messenger RNA", "Modality", "Mus", "Mutant Strains Mice", "Mutation", "NK Cell Activation", "Natural Killer Cells", "Neuraminidase", "Outcome", "Phenotype", "Phylogenetic Analysis", "Play", "Probability", "Production", "Proteins", "Public Health", "RNA vaccine", "Reporting", "Research", "Role", "Seasons", "Tandem Repeat Sequences", "Testing", "United States National Institutes of Health", "Vaccination", "Vaccines", "Variant", "Virus", "antibody-dependent cell cytotoxicity", "chemokine", "cross immunity", "cytokine", "design", "efficacy testing", "flexibility", "flu", "immunogenic", "immunogenicity", "in vitro Assay", "in vivo", "influenza virus vaccine", "influenzavirus", "innovation", "insight", "lipid nanoparticle", "mRNA lipid nano particle vaccine", "mouse model", "neutralizing vaccine", "novel", "novel strategies", "pandemic potential", "pathogen", "receptor binding", "seasonal influenza", "stem", "universal influenza vaccine", "universal vaccine", "vaccination strategy", "vaccine candidate", "vaccine efficacy", "vaccine immunogenicity", "vaccine platform", "vaccine strategy", "virology" ], "approved": true } }, { "type": "Grant", "id": "15895", "attributes": { "award_id": "3R01AI170564-04S1", "title": "Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44333, "first_name": "ELEANORE JENNIFER", "last_name": "CHUANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2027-07-31", "award_amount": 139891, "principal_investigator": { "id": 24638, "first_name": "Supriya Dinesh", "last_name": "Mehta", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 163, "ror": "https://ror.org/02mpq6x41", "name": "University of Illinois at Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 3396, "ror": "", "name": "RUSH UNIVERSITY MEDICAL CENTER", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "In western Kenya, HIV prevalence is 16% among women in the general population, and 29% among the most economically constrained women. The HIV/STI epidemic overlaps with broader reproductive health concerns. Menstrual hygiene management (MHM) is a pervasive problem across low- and middle-income countries. In Phillips-Howards’ survey of over 3,400 women in rural Kenya, two-thirds of women in impoverished settings state they depend on their sexual partners to provide branded products. Economically vulnerable women at high risk for HIV and STI are uniquely challenged because many continue to have sex during menses, and engage in harmful MHM practices, such as vaginal insertion of sponges and cotton to maintain dryness. Led by co-investigator Phillips-Howard, a cluster-randomized study of 644 girls aged 14-16 years old in western Kenya compared reusable menstrual cups to usual menstrual practice and counseling; after 9 months, menstrual cup use resulted in 35% reduction (p=0.034) in Bacterial vaginosis (BV) prevalence and 56% reduction (p=0.001) in STI prevalence compared to other materials. Among 431 Kenyan secondary schoolgirls aged 14-21, we observed cloth use for menses was associated with a 1.72-fold increased odds of non-optimal vaginal microbiome (CST-IV vs. CST-I: aOR=1.90; 95% CI: 1.03–2.86). Over 18 months of observation prior to COVID-19, girls using menstrual cups to manage menses had 20% higher occurrence of Lactobacillus crispatus dominated CST-I (aRR=1.29; 95% CI: 1.08–1.53, controlling for age, and baseline STI and sexual activity). Menstrual cups designed for use during intercourse may help women prevent BV and STIs through hygienic menstrual practices and avoidance of harmful practices to maintain vaginal dryness during menses. Objective: This single-arm interventional trial seeks to evaluate the preliminary efficacy of menstrual cups on non-optimal vaginal microbiome (VMB), BV, and STIs of economically vulnerable women at high risk for STIs and HIV, assess safety profile, and understand implementation needs. In Aim 1, we will evaluate the impact of menstrual cups on VMB, BV, and STIs among 402 economically vulnerable women in semi-urban Kenya. In Aim 2, we will conduct integrated surveillance for enhanced detection of safety endpoints, risk of cup contamination, and mitigating or facilitating water, sanitation, hygiene (WASH) factors. In Aim 3, we will identify constructs for successful MHM program implementation using an implementation science framework. Future Directions: The biological protection suggested in a randomized setting, and our findings that unhygienic cloth use is associated with non-optimal VMB, while menstrual cup use increases optimal VMB composition, together provide rational justification for this trial, of relevance to economically challenged women globally. Assessing preliminary efficacy signal in conjunction with implementation characteristics and adverse events, will generate a comprehensive and necessary foundation for definitive assessment of effectiveness of menstrual cups as a multipurpose intervention for MHM, and to reduce BV and STIs.", "keywords": [ "16 year old", "Acceleration", "Address", "Adverse event", "Age", "Bacterial Vaginosis", "Behavioral", "Biological", "COVID-19", "Characteristics", "Chlamydia", "Counseling", "Data", "Decision Making", "Detection", "Discrimination", "Dryness", "Education", "Eligibility Determination", "Epidemic", "Extravasation", "Financial Support", "Focus Groups", "Foundations", "Future", "General Population", "Gonorrhea", "Gossypium", "Guidelines", "HIV", "HIV/STD", "Health Care", "High Risk Woman", "Hygiene", "Individual", "Intervention", "Intervention Trial", "Interview", "Investigation", "Kenya", "Knowledge", "Lactobacillus", "Life", "Location", "Medical", "Menstruation", "Odors", "Participant", "Phase", "Policies", "Porifera", "Poverty", "Practice Management", "Prevalence", "Privacy", "Randomized", "Reporting", "Reproductive Health", "Research Personnel", "Risk", "Rural", "Safety", "Sanitation", "Secondary Schools", "Secrecy", "Sex Behavior", "Sexual Partners", "Signal Transduction", "Soaps", "Surveys", "Taboo", "Technology", "Time", "Training", "Trichomonas Infections", "UNESCO", "Vagina", "Water", "Woman", "Wool", "Work", "aged", "arm", "biobehavior", "contextual factors", "cost", "cost effective", "cost effective intervention", "design", "diverse data", "effectiveness evaluation", "girls", "global health", "implementation context", "implementation determinants", "implementation evaluation", "implementation framework", "improved", "low and middle-income countries", "microbiome composition", "pandemic disease", "pharmacovigilance", "prevent", "primary outcome", "programs", "safety assessment", "scale up", "sex", "sexual and reproductive health", "social", "social stigma", "stem", "treatment arm", "trial design", "vaginal dryness", "vaginal microbiome", "women's reproductive health" ], "approved": true } }, { "type": "Grant", "id": "15896", "attributes": { "award_id": "1F30AI186615-01A1", "title": "HIV and its impact on Long COVID prevalence and manifestations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44334, "first_name": "ZUOYU", "last_name": "XU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-22", "end_date": "2028-08-21", "award_amount": 43420, "principal_investigator": { "id": 44335, "first_name": "Skye", "last_name": "Opsteen", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3397, "ror": "", "name": "UNIVERSITY OF ALABAMA AT BIRMINGHAM", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this NIH F30 application is to support the PI, Skye Opsteen, and her mentored research and career development for the next three years. The proposed activities will strengthen her potential to become a successful physician scientist. The major goal of this project is to develop her experimental immunology skills to inform the biologic basis of post-COVID syndromes, particularly in people with HIV (PWH) given their increased baseline immune activation. The primary objectives of the research proposal are to investigate if the monocyte and T cell population shifts typical of chronic HIV infection are exacerbated during long COVID, and how the immune features of long COVID in PWH compare to people without HIV. Chronic inflammation has been implicated in long COVID development and is known to drive increased rates of comorbidities in PWH; therefore, studying long COVID in PWH offers a unique opportunity to characterize long COVID phenotypes driven by chronic inflammation. This project will investigate monocyte-mediated inflammation, specifically the role of CD16+ monocytes and inflammatory cytokines IL-1 and TNF in recovery versus long COVID development in PWH, and how these responses contribute to clinical symptoms such as fatigue (Aim 1). The project will also determine the contribution of adaptive immune responses during long COVID in PWH (Aim 2). Our long-term objective is to inform future long COVID studies of potential diagnostic markers and therapeutic targets for patients with long COVID phenotypes driven by persistent inflammation. The proposed training plan for the PI is sponsored by her primary PhD mentor, Dr. Nathan Erdmann, and co- mentor, Dr. Paul Goepfert. Included in the training plan are experiences that will help her develop in three major areas: 1) rigorous immunological research in HIV and SARS-CoV-2, which includes developing familiarity with the existing literature, critically evaluating published studies, and training in principles of scientific integrity and responsible conduct of research; 2) competence in bioinformatic techniques and biostatistical analysis; and 3) career and professional development, including grant writing, manuscript review, clear communication through presentation and manuscript preparation, and translation of research findings to clinical applications. After completion, this training plan will provide the PI with the foundation necessary for a successful career as a physician scientist. Her ultimate career goal is to one day lead a translational research laboratory that studies human immune responses to emerging and reemerging pathogens in the setting of chronic immune dysregulation to assist in the clinical prevention and treatment of various infectious diseases in at-risk populations.", "keywords": [ "2019-nCoV", "Adipose tissue", "Affinity", "Antibodies", "Antibody Affinity", "Antibody Formation", "Antigen Presentation", "Area", "Automobile Driving", "Binding", "Bioinformatics", "Biological", "Biological Assay", "Biometry", "Blood", "COVID-19 pathogenesis", "COVID-19 prevalence", "Chronic", "Clinical", "Communicable Diseases", "Communication", "Competence", "Development", "Doctor of Philosophy", "Exhibits", "Extravasation", "FCGR3B gene", "Familiarity", "Fatigue", "Foundations", "Frequencies", "Future", "Gene Expression Profile", "Goals", "Grant", "HIV", "HIV Infections", "Hospitalization", "Human", "Immune", "Immune response", "Immunocompetent", "Immunoglobulin G", "Immunologics", "Immunology", "Impairment", "Individual", "Inflammation", "Inflammatory", "Inflammatory Response", "Laboratory Study", "Lead", "Link", "Literature", "Long COVID", "Macrophage", "Manuscripts", "Mediating", "Mentors", "NF-kappa B", "Patients", "Persons", "Phenotype", "Physicians", "Plasma", "Population", "Populations at Risk", "Predisposition", "Preparation", "Prevention", "Production", "Publishing", "Recovery", "Research", "Research Proposals", "Risk", "Role", "Scientist", "Symptom Burden", "Symptoms", "Syndrome", "T-Lymphocyte", "Techniques", "Tissues", "Training", "Translational Research", "United States National Institutes of Health", "Viral", "Writing", "acute COVID-19", "adaptive immune response", "antiretroviral therapy", "career", "career development", "clinical application", "comorbidity", "cytokine", "diagnostic biomarker", "emerging pathogen", "exhaustion", "experience", "immune activation", "insight", "mitochondrial dysfunction", "monocyte", "persistent symptom", "post SARS-CoV-2 infection", "post-COVID-19", "programmed cell death protein 1", "receptor", "research and development", "response", "responsible research conduct", "severe COVID-19", "skills", "therapeutic target" ], "approved": true } }, { "type": "Grant", "id": "15902", "attributes": { "award_id": "1F31AI191716-01", "title": "The evolutionary genetic basis for changes in viral receptor-binding specificities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-01", "end_date": "2028-06-30", "award_amount": 41963, "principal_investigator": { "id": 44339, "first_name": "Caroline", "last_name": "Craig", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3398, "ror": "", "name": "UNIVERSITY OF UTAH", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "In this proposal, I discuss my plans to use a high-throughput yeast display platform to dissect the essential changes that occur in viral protein binding specificities. I am using the coronavirus family for my investigations because there are instances of species specificity changes of interest in the SARS-related coronaviruses that are of interest, as well as instances of wholesale receptor changes in the MERS-related coronaviruses. Thus far, this work has begun to find the substitutions of interest along the gains of human ACE2 binding in the SARS-related coronaviruses. From preliminary results, we can see one substitution that is highly associated with mutations that can bind human ACE2. In addition, I have started to parse out the important branch where the wholesale receptor change occurred along the MERS-related coronavirus family phylogenetic tree. These changes are particularly interesting because the evolutionary genetic basis for these receptor-binding specificity changes has not been characterized. Through this research, I will inform the field of the necessary changes that need to occur for viruses to switch receptors as well as what effects species specificity has on these receptor binding dynamics. Overall, this work will be important for the field, too, because it will lay a foundation of how these viruses are gaining the ability to spillover from their animal reservoirs and into humans. Zoonotic transmission, or viruses gaining the ability to bind human receptors, is a major threat to human health, as we know from the SARS-CoV-2 pandemic and the MERS epidemic, for instance.", "keywords": [ "ACE2", "Affect", "Affinity", "Animals", "Antibodies", "Binding", "Binding Proteins", "Biological Assay", "Biophysical Process", "COVID-19 pandemic", "Chiroptera", "Coronavirus", "Data", "Enabling Factors", "Endowment", "Epidemic", "Event", "Evolution", "Family", "Foundations", "Genetic", "Genetic Drift", "Glycoproteins", "Health", "Human", "Infection", "Investigation", "Maps", "Mediating", "Merbecovirus", "Middle East Respiratory Syndrome", "Modeling", "Molecular", "Mutation", "Phenotype", "Phylogenetic Analysis", "Positioning Attribute", "Recording of previous events", "Research", "SARS coronavirus", "Sarbecovirus", "Species Specificity", "Specificity", "Techniques", "Testing", "Trees", "Tropism", "Vaccines", "Viral", "Viral Proteins", "Virus", "Virus Receptors", "Work", "Yeasts", "Zoonoses", "arms race", "candidate identification", "design", "insight", "interest", "mutation screening", "novel", "pandemic disease", "pandemic virus", "pressure", "prevent", "protein structure", "receptor", "receptor binding", "spillover event", "trait", "transmission process", "zoonotic spillover" ], "approved": true } }, { "type": "Grant", "id": "15913", "attributes": { "award_id": "1R21AI194204-01", "title": "Notch regulation of airway epithelial-immune cell cross-talk in SARS-CoV-2 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32599, "first_name": "MICHELLE MARIE", "last_name": "ARNOLD", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-09", "end_date": "2027-06-30", "award_amount": 448688, "principal_investigator": { "id": 44356, "first_name": "Susan", "last_name": "Kovats", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44357, "first_name": "Matthew Stuart", "last_name": "Walters", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3399, "ror": "", "name": "OKLAHOMA MEDICAL RESEARCH FOUNDATION", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19. Infection with SARS-CoV-2 begins in epithelial cells of the upper airways, which triggers multiple antiviral responses that activate myeloid immune cells, coordinate the early innate immune response, and limit viral spread. Notably, our understanding of the cell signaling mechanisms that regulate early epithelial-immune cell interactions and induction of tissue pathology during SARS-CoV-2 infection of the human airway remains limited. To investigate these processes, we have developed a novel in vitro all human 3D model of the upper airways (HUA) composed of layers of primary differentiated airway epithelial cells expressing ACE2, lung fibroblasts in a collagen matrix, and pulmonary endothelial cells, with myeloid cells present in each layer. SARS-CoV-2 infection of the HUA model results in virus replication and induction of an immune response reminiscent of in vivo infection, and the presence of myeloid cells limits viral replication. Therefore, we will use the HUA model to perform kinetic studies of the mechanisms by which human airway cells interact to regulate virus-host interactions, inflammation, and tissue pathology associated with SARS-CoV-2. We will focus on the Notch pathway, which acts via direct cell- to-cell signaling to regulate airway epithelial cell fate decisions as well as myeloid cell maintenance, Toll-like receptor signaling, pro-inflammatory polarization, and antiviral functions. However, the mechanisms by which Notch signaling regulates airway epithelial-myeloid cell interactions during SARS-CoV-2 infection remain unknown. Our preliminary analyses showed that airway epithelial cells and myeloid cells express multiple Notch ligands and receptors in uninfected HUA models, suggesting that the Notch pathway will mediate bidirectional crosstalk during the airway response to infection. We will test the central hypothesis that Notch receptor signaling in myeloid cells regulates their pro-inflammatory phenotype, thereby promoting the host innate antiviral immune response and contributing to airway epithelial cell damage and remodeling during SARS-CoV-2 infection. Using lentivirus vectors and inducible expression systems, we will attenuate expression of individual Notch ligands and receptors in a cell-type specific and temporal manner. Following SARS-CoV-2 infection, we will quantify the impact of reducing Notch signaling activity on virus replication, myeloid cell phenotypes, the host immune response, and airway epithelial remodeling. The data collected in this study will advance our understanding of the mechanisms that regulate airway epithelial-immune cell interactions during SARS-CoV-2 infection and may identify candidate therapeutic targets in the Notch pathway to enhance antiviral immunity and reduce epithelial injury and remodeling in the upper airway.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Anti-viral Response", "Anti-viral Therapy", "Attenuated", "COVID-19", "COVID-19 treatment", "Cell Communication", "Cell Differentiation process", "Cell Maintenance", "Cell Separation", "Cells", "Cessation of life", "Collagen", "Data", "Dendritic Cells", "Endothelial Cells", "Environment", "Epithelial Cells", "Epithelium", "Fibroblasts", "Gene Modified", "Human", "Immune", "Immune response", "In Vitro", "Individual", "Infection", "Inflammation", "Inflammatory", "Innate Immune Response", "Kinetics", "Lentivirus Vector", "Ligands", "Lung", "Macrophage", "Maintenance", "Mediating", "Membrane", "Modeling", "Myelogenous", "Myeloid Cells", "NOTCH1 gene", "Notch Signaling Pathway", "Pathology", "Pathway interactions", "Phenotype", "Play", "Process", "Receptor Signaling", "Regulation", "Role", "SARS-CoV-2 infection", "Shapes", "Signal Transduction", "Structure of parenchyma of lung", "System", "Testing", "Tissue Model", "Tissues", "Toll-like receptors", "Viral", "Viral Physiology", "Virus", "Virus Activation", "Virus Replication", "airway epithelium", "antiviral immunity", "candidate identification", "cell injury", "cell type", "epithelial injury", "human disease", "in vivo", "inducible gene expression", "lung injury", "lung microvascular endothelial cells", "lung repair", "monocyte", "notch protein", "novel", "pandemic disease", "post SARS-CoV-2 infection", "pulmonary", "receptor", "respiratory infection virus", "respiratory virus", "response", "single-cell RNA sequencing", "therapeutic target", "three-dimensional modeling", "virus host interaction" ], "approved": true } }, { "type": "Grant", "id": "15924", "attributes": { "award_id": "1R21AI190938-01", "title": "Identification and enrichment of signature regions of antimicrobial resistant pathogen genomes for wastewater disease surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32875, "first_name": "INKA I", "last_name": "SASTALLA", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-24", "end_date": "2027-06-30", "award_amount": 421673, "principal_investigator": { "id": 44369, "first_name": "Lauren", "last_name": "Stadler", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3400, "ror": "", "name": "RICE UNIVERSITY", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Antimicrobial resistance is recognized as a global public health threat that makes infections more difficult to treat and increases the risk of other medical procedures. Global and local surveillance of antimicrobial resistance is critical to understanding transmission of resistant pathogens, detecting the emergence of resistance mechanisms, and mitigating the spread of resistant pathogens. Wastewater surveillance represents a powerful, resource-efficient, and comprehensive approach for population-level surveillance of infectious diseases. It has been widely applied to track COVID-19 and other respiratory virus levels in communities, as well as identify circulating variants. However, wastewater surveillance of antimicrobial resistant pathogens has not been widely implemented because of specific challenges that limit its actionability (i.e., the direct use of the surveillance data to inform public health action). This is because antimicrobial resistance is ubiquitous in the environment and even clinically-important antibiotic resistance genes (ARGs) are abundant and widespread in wastewater. Thus, previous approaches that quantified ARGs generated information that was not specific to antimicrobial resistant pathogens. This proposal focuses on the development of foundational computational tools and laboratory methods necessary to identify and detect signature regions of antimicrobial resistant pathogens for wastewater surveillance. Signature regions are defined as genomic regions that are conserved in a pathogen strain but not found in neighboring strains or other genomes. We propose to develop a genomic language model approach to identify signature regions of target antimicrobial resistant pathogens. This will be integrated with a fully automated design pipeline for quantitative assay design. On the wet lab side, we will use microdroplet encapsulation of wastewater microbes to do high-throughput enrichment and isolation of antimicrobial resistant bacteria. This approach will enable sensitive and specific detection of antimicrobial resistant pathogens by encapsulating individual cells and assaying them for signature regions using digital droplet PCR. The proposed computational and laboratory tools will result in software and wet lab methodologies that can be used by public health laboratories and wastewater surveillance programs for specific and sensitive antimicrobial resistance monitoring. Software, assays, and protocols will be made publicly available and can also be applied for other pathogen targets. Advancing the actionability of antimicrobial resistance wastewater monitoring has the potential to enable the prediction of outbreaks, forecast hospitalizations, guide treatment decisions, understand transmission, and evaluate mitigation strategies for antimicrobial resistant infections.", "keywords": [ "2019-nCoV", "Adoption", "Antibiotic Resistance", "Antimicrobial Resistance", "Behavior", "Biological Assay", "COVID-19", "Cells", "Circulation", "Cities", "Classification", "Clinical", "Communicable Diseases", "Communities", "Complement", "Complex", "Computer software", "Computing Methodologies", "Death Rate", "Decision Making", "Detection", "Development", "Disease Surveillance", "Emulsions", "Encapsulated", "Environment", "Extended spectrum Beta lactamase producing Escherichia coli", "Extended-spectrum β-lactamase", "Genes", "Genome", "Genomic Segment", "Genomics", "Goals", "Health", "Health Care Costs", "Health Care Facility", "Health Care Systems", "Hospitalization", "Hospitals", "Individual", "Infection", "Influenza", "Intervention", "Klebsiella pneumoniae", "Knowledge", "Laboratories", "Language", "Length of Stay", "Literature", "Medical", "Methodology", "Methods", "Microbe", "Microfluidics", "Mobile Genetic Elements", "Modeling", "Monitor", "Outcome", "Pathogenicity", "Patient Care", "Persons", "Plasmids", "Population", "Prevalence", "Procedures", "Protocols documentation", "Pseudomonas aeruginosa", "Public Health", "Reporting", "Research", "Resistance", "Resources", "Respiratory syncytial virus", "Risk", "Sampling", "Sensitivity and Specificity", "Side", "Surveillance Program", "Technology", "Vancomycin Resistance", "Vancomycin resistant enterococcus", "Vancomycin-resistant S. aureus", "Variant", "Virus", "antimicrobial resistant infection", "antimicrobial resistant pathogen", "bacterial resistance", "carbapenem resistance", "carbapenemase", "clinical care", "clinical risk", "community transmission", "computational pipelines", "computerized tools", "design", "detection limit", "droplet digital PCR", "genomic signature", "improved", "metagenomic sequencing", "methicillin resistant Staphylococcus aureus", "microbial community", "microbial host", "outbreak prediction", "pathogen", "pathogen genome", "public health intervention", "resistance gene", "resistance mechanism", "resistant strain", "respiratory virus", "surveillance data", "tool", "transmission process", "wastewater monitoring", "wastewater samples", "wastewater surveillance" ], "approved": true } }, { "type": "Grant", "id": "15926", "attributes": { "award_id": "1R13CA301730-01", "title": "CSHL 2025 Conference on Eukaryotic mRNA Processing", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44262, "first_name": "RUIBAI", "last_name": "LUO", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-01", "end_date": "2026-06-30", "award_amount": 15000, "principal_investigator": { "id": 23978, "first_name": "DAVID J.", "last_name": "STEWART", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 992, "ror": "https://ror.org/02qz8b764", "name": "Cold Spring Harbor Laboratory", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 3401, "ror": "", "name": "COLD SPRING HARBOR LABORATORY", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed conference on “Eukaryotic mRNA Processing” will convene scientists studying various aspects of mRNA processing, transport, turnover and their roles in human diseases. Major advances have recently been made in all these areas, and the proposed conference will be a timely event for discussing the latest unpublished results and exchanging ideas, thereby fostering new developments in this rapidly moving field. The proposed conference will be the fifteenth meeting in the series that is held every other year at Cold Spring Harbor Laboratory. The most recent meeting was held in August 2023 and attracted 435 scientists internationally, who are actively investigating various aspects of messenger RNA maturation in eukaryotic cells using genetic, biochemical, molecular, cell biological, and computational approaches. The 2025 meeting will be held in person with a virtual audience for broadening access and for those that cannot attend in person. As in the previous meetings, a major focus of the 2025 meeting will be on nuclear events in mRNA maturation, including mRNA splicing and polyadenylation, the connections between transcription and mRNA maturation steps, the roles of mRNA processing events in the biology of viruses, the application of informatics and genome-wide approaches to the analysis of RNA processing, as well as the relevance of mRNA processing to the etiology of cancer and other diseases. We also expect relevant and timely contributions on topics related to the new coronavirus variant SARS-CoV-2, in particular on the experimental vaccines based on messenger RNA. The meeting will include two keynote lectures, eight plenary oral sessions and two poster sessions. Oral sessions will include ten or five 12-minute talks, respectively, with additional time for discussion. In response to major developments in the fields of RNA modification and the roles of RNA structure in processing, we have expanded the sessions devoted to these topics; this adaptability to the major movements in the field helps keep this meeting at the cutting edge and ensures that we will draw participants from traditional as well as emerging areas of RNA research. This subdivision, successfully piloted at the 2019 meeting, allows a broader representation of scientific fields. As always, except for the two keynote lectures, all speakers will be selected on the basis of the submitted abstracts, which encourages active participation by junior scientists. We will particularly encourage presentation of unpublished work by the students and postdoctoral fellows who are leading these projects, as has traditionally been a hallmark and a unique strength of the Cold Spring Harbor meetings.", "keywords": [ "Acceleration", "Architecture", "Area", "Back", "Binding", "Biochemical", "Biological", "Biology", "Cancer Etiology", "Cancer Model", "Cell Physiology", "Cells", "Communities", "Complement", "DNA Sequence", "Data", "Defect", "Development", "Disease", "Emerging Technologies", "Ensure", "Environment", "Eukaryota", "Eukaryotic Cell", "Event", "Faculty", "Fostering", "Future", "Gene Expression Regulation", "Genes", "Genetic", "Genetic Transcription", "Goals", "Human", "Individual", "Industrialization", "Informatics", "Inherited", "International", "Interruption", "Introns", "Knowledge", "Laboratories", "Location", "Malignant Neoplasms", "Messenger RNA", "Methodology", "Modification", "Molecular", "Movement", "Nervous System Disorder", "Nuclear", "Nuclear Accidents", "Oncogenic", "Oral", "Organism", "Participant", "Persons", "Physiological", "Play", "Polyadenylation", "Postdoctoral Fellow", "Process", "Property", "Proteins", "RNA", "RNA Processing", "RNA Splicing", "RNA analysis", "Reaction", "Regulation", "Regulatory Pathway", "Request for Applications", "Research", "Research Institute", "Research Personnel", "Role", "SARS-CoV-2 variant", "Scientist", "Seasons", "Series", "Shapes", "Structure", "Students", "Syndrome", "Therapeutic", "Time", "Untranslated RNA", "Vaccines", "Virus", "Yeasts", "cell growth", "computing resources", "disease-causing mutation", "genetic approach", "genome editing", "genome resource", "genome-wide", "graduate student", "human disease", "insight", "interest", "lectures", "mRNA Precursor", "man", "meetings", "member", "mouse model", "new technology", "next generation", "novel coronavirus", "posters", "response", "skills", "success", "symposium", "synergism", "therapeutic RNA", "tool", "unpublished works", "virtual" ], "approved": true } } ], "meta": { "pagination": { "page": 1419, "pages": 1424, "count": 14236 } } }